Octreotide Depot

ApprovedSmall molecule

Novartis

Octreotide Depot is one of 160 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

159

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

AcromegalyActive, not recruiting

Diabetic RetinopathyActive, not recruiting

Non-Proliferative Diabetic RetinopathyActive, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

AcromegalyApproved

Active, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Non-Proliferative Diabetic RetinopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Octreotide Depot

Novartis

Approved

1 2

Trodelvy

Gilead

Preclinical

37 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy2 trials

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Terminated· Novartis logo

Novartis·Phase 3·NCT00248131·260 enrolled

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Terminated· Novartis logo

Novartis·Phase 3·NCT00248157·105 enrolled

Diabetic Retinopathy2 trials

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Completed· Novartis logo

Novartis·Phase 3·NCT00130845·312 enrolled

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

Completed· Novartis logo

Novartis·Phase 3·NCT00131144·583 enrolled

Neuroendocrine Cancer1 trial

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Completed· Novartis logo

Novartis·Phase 2·NCT00363051·160 enrolled

Single Dose1 trial

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

Completed· Novartis logo

Novartis·Phase 1·NCT00432068·48 enrolled

Diarrhea1 trial

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Completed· Novartis logo

Novartis·Phase 3·NCT00582426·139 enrolled

4 more indications

Breast Cancer1 trial

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00002967

Prostate Cancer1 trial

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Terminated·UUniversity of Southern California·Phase 2·NCT01469338·9 enrolled

Acromegaly1 trial

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Completed· Novartis logo

Novartis·Phase 4·NCT00376064·20 enrolled

Neuroendocrine Carcinoma1 trial

Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00113360·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Octreotide Depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Octreotide Depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Octreotide Depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Octreotide Depot

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy2 trials

Diabetic Retinopathy2 trials

Neuroendocrine Cancer1 trial

Single Dose1 trial

Diarrhea1 trial

Breast Cancer1 trial

Prostate Cancer1 trial

Acromegaly1 trial

Neuroendocrine Carcinoma1 trial

References

Drug Info

Quick Facts

Related News